Compare Eaton Corporation plc (ETN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Novo Nordisk A/S — how do they compare? Eaton Corporation plc trades at $458.9 (market cap $172.82B), while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| ETN | NVO | |
|---|---|---|
Market Cap | $172.82B | $207.85B |
Sector | Technology | Health |
52-Week High | $459.29 | $63.98 |
52-Week Low | $315.82 | $35.29 |
Enterprise Value | $193.45B | $222.55B |
Dividend Yield | 0.99% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $459.96, up 3.37% with strong technical momentum and bullish moving average signals. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.15 beating expectations of $3.07. Revenue growth continues with 2026 projections at $30.0 billion, though net profit margin is expected to compress to 12.75%. Recent news highlights Eaton's $7 million Air Force contract for quantum computing grid security and strong AI infrastructure demand.
Outlook remains positive with analyst consensus price target of $499.75 (8.6% upside) and unanimous bullish ratings (26 Buy, 0 Sell). Key risks include premium valuation (P/E 45.31) and execution challenges in meeting raised 2026 guidance. The stock's proximity to 52-week highs suggests near-term consolidation potential despite strong fundamental momentum.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
